信達生物瑪仕度肽在華獲批新適應症

健識局

2025/09/24

近日，信達生物製藥集團宣佈旗下產品瑪仕度肽注射液的第二項適應症獲國家藥品監督管理局（NMPA）批准，用於成人2型糖尿病患者的血糖控制。瑪仕度肽注射液是全球首個獲批的用於2型糖尿病的GCG/GLP-1雙受體激動劑。GCG/GLP-1雙受體激動劑在GLP-1受體激動劑的基礎上激動GCG受體，同時改善胰島素分泌不足和胰島素抵抗兩大糖尿病核心致病機制，幫助糖尿病患者更好地控制血糖。本次獲批主要基於兩項...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2570634110"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570634110\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570634110?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-24 20:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2570634110","market":"hk","top_or_hot":-1,"title":"信達生物瑪仕度肽在華獲批新適應症","media":"健識局","content":"<div>\n<p>近日，信達生物製藥集團宣佈旗下產品瑪仕度肽注射液的第二項適應症獲國家藥品監督管理局（NMPA）批准，用於成人2型糖尿病患者的血糖控制。瑪仕度肽注射液是全球首個獲批的用於2型糖尿病的GCG/GLP-1雙受體激動劑。GCG/GLP-1雙受體激動劑在GLP-1受體激動劑的基礎上激動GCG受體，同時改善胰島素分泌不足和胰島素抵抗兩大糖尿病核心致病機制，幫助糖尿病患者更好地控制血糖。本次獲批主要基於兩項...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204548a4412442&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信達生物瑪仕度肽在華獲批新適應症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信達生物瑪仕度肽在華獲批新適應症\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">健識局</strong><span class=\"h-time small\">2025-09-24 20:12</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>近日，信達生物製藥集團宣佈旗下產品瑪仕度肽注射液的第二項適應症獲國家藥品監督管理局（NMPA）批准，用於成人2型糖尿病患者的血糖控制。瑪仕度肽注射液是全球首個獲批的用於2型糖尿病的GCG/GLP-1雙受體激動劑。GCG/GLP-1雙受體激動劑在GLP-1受體激動劑的基礎上激動GCG受體，同時改善胰島素分泌不足和胰島素抵抗兩大糖尿病核心致病機制，幫助糖尿病患者更好地控制血糖。本次獲批主要基於兩項...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204548a4412442&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204548a4412442&s=b\">健識局</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204548a4412442&s=b","article_id":"2570634110","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924204548a4412442&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2570634110","pubTimestamp":1758715956,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，信達生物製藥集團宣佈旗下產品瑪仕度肽注射液的第二項適應症獲國家藥品監督管理局批准，用於成人2型糖尿病患者的血糖控制。瑪仕度肽注射液是全球首個獲批的用於2型糖尿病的GCG/GLP-1雙受體激動劑。兩項研究證明瑪仕度肽在血糖控制和減重方面均優效於安慰劑或度拉糖肽1.5mg，同時均顯示可改善多項心血管代謝、肝臟和腎臟相關指標。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1583":"高瓴概念","BK1589":"北水核心资产","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","01801":"信达生物","BK1161":"生物科技","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC"},"translate_title":"Innovent Biologics Masdotide approved for new indications in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1.5},"content_text":"近日，信達生物製藥集團宣佈旗下產品瑪仕度肽注射液的第二項適應症獲國家藥品監督管理局（NMPA）批准，用於成人2型糖尿病患者的血糖控制。瑪仕度肽注射液是全球首個獲批的用於2型糖尿病的GCG/GLP-1雙受體激動劑。GCG/GLP-1雙受體激動劑在GLP-1受體激動劑的基礎上激動GCG受體，同時改善胰島素分泌不足和胰島素抵抗兩大糖尿病核心致病機制，幫助糖尿病患者更好地控制血糖。本次獲批主要基於兩項III期臨床研究的結果，分別在中國2型糖尿病參與者中驗證瑪仕度肽單藥治療（DREAMS-1，NCT05628311）和聯合口服降糖藥治療（DREAMS-2，NCT05606913）的療效和安全性。兩項研究證明瑪仕度肽在血糖控制和減重方面均優效於安慰劑或度拉糖肽1.5mg，同時均顯示可改善多項心血管代謝、肝臟和腎臟相關指標。運營｜李木子「超低價中標」、內卷式競爭，壓垮一家地方龍頭藥企「張江也空了！」產業園太多，biotech企業不夠用了醫保談判將至，創新藥價格和療效的「性價比」引發爭議","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}